Discovery
AI-guided target discovery across immunology and rare disease.
Nexui unites computational biology, gene engineering, and translational science to bring precision therapies from the lab bench to the people who need them.
Founded by scientists and clinicians, Nexui operates at the intersection of molecular engineering and data-driven discovery. We design therapies that are precise, durable, and accessible.
Our integrated platform shortens the path from target identification to clinical candidate, so promising science reaches the clinic faster and more safely.
AI-guided target discovery across immunology and rare disease.
Cell and gene platforms built for specificity and scale.
Rigorous preclinical models that de-risk clinical entry.
Manufacturing and access strategies designed from day one.

Programmable vectors and engineered cells that correct disease at its source.

Vaccines and biologics that direct the immune system to clear disease with precision.

Molecular assays that detect disease earlier and guide the right treatment.

AI-guided discovery that predicts biology and prioritizes clinical candidates.
A snapshot of our therapeutic candidates and their current development phase.
Whether you're a research partner, investor, or future team member, we'd love to hear from you.